These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11033577)

  • 1. Case studies, practical issues and observations on population and individual bioequivalence.
    Zariffa NM; Patterson SD; Boyle D; Hyneck M
    Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of multilevel models in the evaluation of bioequivalence (II).].
    Liu QL; Shen ZZ; Li XS; Chen F; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Mar; 31(3):333-9. PubMed ID: 20510066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?
    Micheal F; Sayana M; Motial BM
    Curr Drug Metab; 2019; 20(10):835-844. PubMed ID: 31589117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):162-6. PubMed ID: 11332872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Likelihood approach for evaluating bioequivalence of highly variable drugs.
    Du L; Choi L
    Pharm Stat; 2015; 14(2):82-94. PubMed ID: 25408492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Simulation-Based Approach for Comparing the Population Against Average Bioequivalence Statistical Test for the Evaluation of Nasal Spray Products on Spray Pattern and Droplet Size Distribution Parameters.
    Grmaš J; Lužar-Stiffler V; Dreu R; Injac R
    AAPS PharmSciTech; 2019 Jan; 20(1):38. PubMed ID: 30604193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence tests for interchangeability based on two one-sided probabilities.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach.
    Kurumaddali A; Christopher D; Sandell D; Strickland H; Morgan B; Bulitta J; Wiggenhorn C; Stein S; Lyapustina S; Hochhaus G
    AAPS PharmSciTech; 2019 Jul; 20(6):249. PubMed ID: 31286316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data.
    Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S
    AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.